<DOC>
	<DOC>NCT01890473</DOC>
	<brief_summary>The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.</brief_summary>
	<brief_title>Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe</brief_title>
	<detailed_description>SC=Subcutaneous</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Subjects ≥18 years of age Diagnosis of Rheumatoid Arthritis confirmed by participant's physician Disease activity under control Key Change in diseasemodifying antirheumatic drug (DMARD) therapy within 3 months of enrollment Exposure to investigational drug within 4 weeks or 5 half lives whichever is longer Current or prior use of Rituximab ≤6 months Current or prior use of the following within 4 weeks or 5 half lives whichever is longer: biologic DMARDS, Tofacitinib, Cyclophosphamide, Mycophenolate Mofetil &amp; dPenicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>